Teva Respiratory seeks to raise asthma awareness in Philadelphia
PHILADELPHIA A subsidiary of Teva is hosting asthma awareness events in the Philadelphia area.
Teva Respiratory is partnering with the Philadelphia Phillies to host Asthma Awareness Night at Citizens Bank Park on World Asthma Day (May 4), as well as supporting National Asthma and Allergy Awareness Month as a platinum sponsor of the American Lung Association’s 7th Annual Philadelphia Asthma Walk on May 1. Philadelphia recently was ranked No. 8 among the Asthma and Allergy Foundation of America’s Asthma Capitals ratings.
Additionally, Teva Respiratory’s “Phillies Asthma Awareness Night” will feature free asthma and exercise-induced bronchospasm screenings to benefit the citizens of the City of Brotherly Love.
For a listing of free screening locations, visit AsthmaAndAllergyRelief.org. For more information about Teva’s ongoing commitment to asthma awareness and education, please visit TevaRespiratory.com and EIBLandmarkSurvey.com.
FDA approves new use for Abbott HIV drug
ABBOTT PARK, Ill. The Food and Drug Administration has approved a new use for an HIV drug made by Abbott, the drug maker said Wednesday.
Abbott announced the approval of Kaletra (lopinavir and ritonavir) as a once-daily treatment of adults with HIV who previously have taken antiretroviral therapy. The drug already is approved as a once-daily treatment for patients who have not taken antiretroviral drugs.
“Adherence to treatment is critical to the effective management of HIV,” Baylor College of Medicine Department of Internal Medicine clinical instructor Joseph Gathe said on behalf of Abbott. “A Kaletra once-daily regimen can simplify HIV treatment and offers greater flexibility for patients.”
J&J to pay more than $80 million for unapproved promotion of Topamax
TITUSVILLE, N.J. A Johnson & Johnson subsidiary will pay more than $80 million to the federal government to settle a case involving alleged promotion of an epilepsy drug for uses not approved by the Food and Drug Administration, J&J said Thursday.
In addition to the $81.5 million plus interest that Ortho-McNeil-Janssen Pharmaceuticals will pay to the federal government, a subsidiary of Ortho-McNeil-Janssen itself, Ortho-McNeil Pharmaceutical, will accept a misdemeanor charge concerning promotion of Topamax (topiramate) between 2001 and 2003.
According to the plea agreement, Ortho-McNeil Pharmaceutical promoted Topamax for unapproved uses. The settlement follows a $520 million settlement between the government and AstraZeneca Tuesday concerning alleged off-label marketing of the bipolar disorder and schizophrenia treatment Seroquel (quetiapine fumarate).